PDCD1LG2 and neoplasm: Therefore, the underlying mechanism of therapeutic response to PD-1 blockade in Hodgkin lymphoma could be explained by the fact that the disruption of PD-1/PD-L1 or PD-L2 interaction initiates a cascade of signaling events that reverses the exhausted phenotype in T cells and triggers an effective immune cell response against tumor cells24.